0001883850-22-000143.txt : 20221230
0001883850-22-000143.hdr.sgml : 20221230
20221230161022
ACCESSION NUMBER: 0001883850-22-000143
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221228
FILED AS OF DATE: 20221230
DATE AS OF CHANGE: 20221230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COLES N ANTHONY
CENTRAL INDEX KEY: 0001197018
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 221502084
MAIL ADDRESS:
STREET 1: MORRIS CORP. CENTER I; BLDG. B; 4TH FLR.
STREET 2: 300 INTERPACE PARKWAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2022-12-28
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001197018
COLES N ANTHONY
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2022-12-28
4
M
0
2145
374.12
A
3238
D
Common Stock
2022-12-28
4
M
0
3613
482.68
A
6851
D
Common Stock
2022-12-28
4
S
0
181
707.87
D
6670
D
Common Stock
2022-12-28
4
S
0
1
709.92
D
6669
D
Common Stock
2022-12-28
4
S
0
679
710.63
D
5990
D
Common Stock
2022-12-28
4
S
0
100
711.95
D
5890
D
Common Stock
2022-12-28
4
S
0
1198
713.66
D
4692
D
Common Stock
2022-12-28
4
S
0
1022
714.61
D
3670
D
Common Stock
2022-12-28
4
S
0
2266
715.48
D
1404
D
Common Stock
2022-12-28
4
S
0
311
716.08
D
1093
D
Non-Qualified Stock Option (right to buy)
374.12
2022-12-28
4
M
0
2145
0.0
D
2030-01-02
Common Stock
2145
0
D
Non-Qualified Stock Option (right to buy)
482.68
2022-12-28
4
M
0
3613
0.0
D
2031-01-04
Common Stock
3613
0
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles
2022-12-29